Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D Shinde, Stergios Boussios, Anand Sharma, Prantik Das, Nikhil Vasdev, Sara E Rebuzzi, Yüksel Ürün, Ravindran Kanesvaran, Akash Maniam, Giuseppe L Banna
PURPOSE OF REVIEW: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care. RECENT FINDINGS: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer...
April 23, 2024: Current Oncology Reports